NO165543C - Analogifremgangsmaate for fremst av terapeutisk aktiv (4r,5s,6s,8r,2's,-4's)-3- 4-(dimethylamino-carbonyl)-pyrrolidinhylthio -4-methyl-6-(1-hydroxyethyl)-1-azabicyclo- 3,2,0 hept-2-en-7-on-2-carboxylsyre i krystallinsk form. - Google Patents

Analogifremgangsmaate for fremst av terapeutisk aktiv (4r,5s,6s,8r,2's,-4's)-3- 4-(dimethylamino-carbonyl)-pyrrolidinhylthio -4-methyl-6-(1-hydroxyethyl)-1-azabicyclo- 3,2,0 hept-2-en-7-on-2-carboxylsyre i krystallinsk form.

Info

Publication number
NO165543C
NO165543C NO873205A NO873205A NO165543C NO 165543 C NO165543 C NO 165543C NO 873205 A NO873205 A NO 873205A NO 873205 A NO873205 A NO 873205A NO 165543 C NO165543 C NO 165543C
Authority
NO
Norway
Prior art keywords
pyrrolidinhylthio
hept
dimethylamino
promotion
hydroxyethyl
Prior art date
Application number
NO873205A
Other languages
English (en)
Norwegian (no)
Other versions
NO873205D0 (no
NO165543B (no
NO873205L (no
Inventor
Makoto Sunagawa
Yutaka Isobe
Yutaka Takeuchi
Haruki Matsumura
Tetsuo Noguchi
Yukio Ozaki
Original Assignee
Sumitomo Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma filed Critical Sumitomo Pharma
Publication of NO873205D0 publication Critical patent/NO873205D0/no
Publication of NO873205L publication Critical patent/NO873205L/no
Publication of NO165543B publication Critical patent/NO165543B/no
Publication of NO165543C publication Critical patent/NO165543C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
    • C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
    • C07D477/16—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hetero atoms or carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 3
    • C07D477/20—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO873205A 1986-07-30 1987-07-30 Analogifremgangsmaate for fremst av terapeutisk aktiv (4r,5s,6s,8r,2's,-4's)-3- 4-(dimethylamino-carbonyl)-pyrrolidinhylthio -4-methyl-6-(1-hydroxyethyl)-1-azabicyclo- 3,2,0 hept-2-en-7-on-2-carboxylsyre i krystallinsk form. NO165543C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17932186 1986-07-30
JP15776987 1987-06-26

Publications (4)

Publication Number Publication Date
NO873205D0 NO873205D0 (no) 1987-07-30
NO873205L NO873205L (no) 1988-02-01
NO165543B NO165543B (no) 1990-11-19
NO165543C true NO165543C (no) 1991-02-27

Family

ID=26485103

Family Applications (2)

Application Number Title Priority Date Filing Date
NO873205A NO165543C (no) 1986-07-30 1987-07-30 Analogifremgangsmaate for fremst av terapeutisk aktiv (4r,5s,6s,8r,2's,-4's)-3- 4-(dimethylamino-carbonyl)-pyrrolidinhylthio -4-methyl-6-(1-hydroxyethyl)-1-azabicyclo- 3,2,0 hept-2-en-7-on-2-carboxylsyre i krystallinsk form.
NO1997013C NO1997013I1 (no) 1986-07-30 1997-10-17 Meropenem

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO1997013C NO1997013I1 (no) 1986-07-30 1997-10-17 Meropenem

Country Status (20)

Country Link
US (1) US4888344A (da)
EP (1) EP0256377B1 (da)
JP (1) JP2665767B2 (da)
AR (1) AR243189A1 (da)
AU (1) AU596857B2 (da)
CA (1) CA1322371C (da)
DE (1) DE3781980T2 (da)
DK (1) DK172666B1 (da)
ES (1) ES2052524T3 (da)
FI (1) FI88037C (da)
GR (1) GR3006254T3 (da)
HK (1) HK169595A (da)
HU (1) HU199473B (da)
IE (1) IE60588B1 (da)
IL (1) IL83372A (da)
LU (1) LU88635I2 (da)
MX (1) MX173359B (da)
NO (2) NO165543C (da)
NZ (1) NZ221224A (da)
PH (1) PH24710A (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
KR880006244A (ko) * 1986-11-24 1988-07-22 후지사와 도모 기찌 로 3-피롤리디닐티오-1-아자바이스클로[3.2.0]햅트2-엔-2-카르복실산 화합물 및 이의 제조방법
DE69019610D1 (de) * 1989-07-06 1995-06-29 Banyu Pharma Co Ltd Cyclische Derivate des Amidinylthiocarbapenems.
CA2033390A1 (en) * 1989-12-29 1991-06-30 Susumu Nakagawa 2-(2-cyclopropylpyrrolidin-4-ylthio) carbapenem derivatives
TW264475B (da) * 1991-09-20 1995-12-01 Takeda Pharm Industry Co Ltd
JP2696807B2 (ja) * 1992-08-06 1998-01-14 田辺製薬株式会社 カルバペネム誘導体の製法
GB9503717D0 (en) * 1995-02-24 1995-04-12 Smithkline Beecham Plc Novel compounds
FR2735474B1 (fr) * 1995-06-13 1997-08-08 Roussel Uclaf Chlorhydrate de zilpaterol sous une forme cristallisee particuliere, son procede de preparation et les produits intermediaires mis en oeuvre
US6432401B2 (en) 2000-05-12 2002-08-13 Novalar Pharmaceuticals, Inc. Local anesthetic methods and kits
PL335048A1 (en) * 1997-02-07 2000-03-27 Kyoto Pharmaceutical Ind Carbapenemic compounds, thier usage and intermediate compounds used in their production
SK16382000A3 (sk) 1998-05-01 2001-05-10 Kyoto Pharmaceutical Industries, Ltd. Karbapénové deriváty, ich vyžitie a ich medziproduktové zlúčeniny
AU5105100A (en) * 1999-06-03 2000-12-28 Eisai Co. Ltd. Crystals of carbapenem derivatives and pharmaceutical preparations for injection
US7041660B2 (en) 1999-07-06 2006-05-09 Sankyo Company, Limited Crystalline 1-methylcarbapenem derivatives
TWI250160B (en) * 1999-07-06 2006-03-01 Sankyo Co Crystalline 1-methylcarbapenem compound
JP5079190B2 (ja) * 2001-04-27 2012-11-21 大日本住友製薬株式会社 アゼチジノン誘導体およびその製造方法
YU92003A (sh) * 2001-05-21 2006-05-25 Kyoto Pharmaceutical Industries Ltd. Karbapenem jedinjenje
KR100451672B1 (ko) * 2001-06-05 2004-10-08 한미약품 주식회사 결정성 세프디니르 산부가염, 이의 제조방법 및 이를이용한 세프디니르의 제조방법
EP1426376A4 (en) * 2001-08-13 2004-12-22 Eisai Co Ltd PROCESS FOR THE PREPARATION OF CARBAPENEM-BASED ANTIBIOTICS
WO2003026572A2 (en) 2001-09-26 2003-04-03 Merck & Co., Inc. Crystalline forms of ertapenem sodium
KR100628676B1 (ko) * 2001-09-26 2006-09-27 머크 앤드 캄파니 인코포레이티드 카바페넴 화합물의 제조방법
ITMI20012364A1 (it) * 2001-11-09 2003-05-09 Antibioticos Spa Processo di sintesi della cefixima via alchil-o arilsolfonati
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US20030236306A1 (en) * 2002-06-20 2003-12-25 Chen Andrew X. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
US7229630B2 (en) * 2002-06-20 2007-06-12 Novalar Pharmaceuticals, Inc. Stabilized formulations of alpha adrenergic receptor antagonists and the uses thereof
EP1950563A3 (en) 2002-09-11 2008-08-06 Michio Ishibashi Method for screening for a substance for promoting regeneration of macrophages
US20070249827A1 (en) * 2004-06-02 2007-10-25 Sandoz Ag Meropenem Intermediatein in Crystalling Form
WO2006035300A2 (en) * 2004-09-30 2006-04-06 Ranbaxy Laboratories Limited A process for the preparation of meropenem
JP4547245B2 (ja) * 2004-12-16 2010-09-22 株式会社パーマケム・アジア ペリンドプリルエルブミンのｉ型結晶、及びその製造方法
US8501818B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US8501817B2 (en) * 2005-03-14 2013-08-06 Ceptaris Therapeutics, Inc. Stabilized compositions of alkylating agents and methods of using same
US20110039943A1 (en) * 2005-03-14 2011-02-17 Robert Alonso Methods for treating skin disorders with topical nitrogen mustard compositions
US7872050B2 (en) * 2005-03-14 2011-01-18 Yaupon Therapeutics Inc. Stabilized compositions of volatile alkylating agents and methods of using thereof
US20070197781A1 (en) * 2005-07-29 2007-08-23 Neera Tewari Processes for the preparation of carbapenems
WO2007029084A2 (en) 2005-09-05 2007-03-15 Ranbaxy Laboratories Limited A process for the preparation of carbapenem compounds
EP1934221A4 (en) 2005-09-15 2011-10-26 Orchid Chemicals & Pharm Ltd IMPROVED METHOD FOR THE PRODUCTION OF BETA LACTAM ANTIBIOTICS
CN100497338C (zh) * 2006-01-05 2009-06-10 上海医药工业研究院 4－甲基－7－氧－1－氮杂双环[3.2.0]庚－2－烯－2－羧酸类衍生物的制备方法
KR100781821B1 (ko) * 2006-02-16 2007-12-03 문순구 카르바페넴계 화합물의 제조방법
JP5373390B2 (ja) * 2006-03-28 2013-12-18 株式会社カネカ カルバペネム化合物の改良された製造方法
US8093378B2 (en) * 2006-04-28 2012-01-10 Kaneka Corporation Crystallization method for intermediates of carbapenem antibiotics
WO2009075309A1 (ja) * 2007-12-12 2009-06-18 Dainippon Sumitomo Pharma Co., Ltd. 製剤組成物
US20090216010A1 (en) * 2008-02-22 2009-08-27 Wei-Hong Tseng Crystalline carbapenem compound and produced method thereof
EP2098525A1 (en) 2008-02-26 2009-09-09 Savior Lifetec Corporation Crystalline carbapenem compound and produced method thereof
US8097719B2 (en) * 2008-07-15 2012-01-17 Genesen Labs Meropenem intermediate in novel crystalline form and a method of manufacture of meropenem
AU2009277936B2 (en) * 2008-07-30 2014-11-27 Sun Pharmaceutical Industries Limited Process for the preparation of carbapenem compounds
ES2477290T3 (es) * 2009-03-13 2014-07-16 Daewoong Pharmaceutical Co., Ltd. Método mejorado para preparar meropenem usando polvo de zinc
WO2011048583A1 (en) 2009-10-23 2011-04-28 Ranbaxy Laboratories Limited Process for the preparation of carbapenem compounds
WO2011141847A1 (en) * 2010-05-10 2011-11-17 Orchid Chemicals And Pharmaceuticals Limited An improved process for the preparation of meropenem
PL2630147T3 (pl) 2010-10-22 2015-08-31 Ranbaxy Laboratories Ltd Sposób otrzymywania czystego trihydratu meropenemu
CN101962383A (zh) * 2010-11-12 2011-02-02 上海巴迪生物医药科技有限公司 一种美罗培南的合成方法
WO2012081033A2 (en) * 2010-12-06 2012-06-21 Sequent Scientific Limited A process for preparation of imipenem
CN102532140B (zh) * 2010-12-21 2015-03-11 北大方正集团有限公司 一种美罗培南三水合物的制备方法
CN102250096B (zh) * 2011-09-05 2016-04-06 江西华邦药业有限公司 一种美罗培南的制备方法
CN103570720B (zh) * 2012-07-31 2016-02-10 新乡海滨药业有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
CN103570718B (zh) * 2012-07-31 2016-06-29 深圳市海滨制药有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
CN103570719B (zh) * 2012-07-31 2016-03-02 深圳市海滨制药有限公司 一种美罗培南原料药、其制备方法及包含其的药物组合物
KR101331762B1 (ko) * 2012-12-28 2013-11-20 주식회사 대웅제약 메로페넴의 삼수화물의 제조방법
CN103044429B (zh) * 2013-01-28 2015-04-01 苏州二叶制药有限公司 一种美罗培南的制备方法
CA2899342C (en) 2013-02-01 2021-09-21 Ocularis Pharma, Llc Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
DK2950648T3 (da) 2013-02-01 2019-12-02 Ocuphire Pharma Inc Vandige oftalmiske opløsninger af phentolamin og medicinske anvendelser deraf
KR102144777B1 (ko) 2013-06-19 2020-08-18 제이더블유중외제약 주식회사 결정형 메로페넴 삼수화물의 제조방법
GB2529738B (en) * 2014-03-27 2018-10-17 Johnson Matthey Plc Process for preparing a carbapenem antibiotic
JP2022508715A (ja) 2018-10-15 2022-01-19 オキュフィア・ファーマ・インコーポレイテッド 緑内障および関連状態の処置のための方法および組成物
DK3870170T3 (da) 2018-10-26 2026-05-26 Opus Genetics Inc Behandling af presbyopi og mydriasis med fentolamin
CN115368310B (zh) 2021-05-18 2025-06-27 奥库菲尔医药公司 合成甲磺酸酚妥拉明的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK153486C (da) * 1978-07-03 1988-11-28 Merck & Co Inc Analogifremgangsmaade til fremstilling af krystallinsk n-formimidoyl-thienamycin-monohydrat
EP0113101A1 (en) * 1982-12-30 1984-07-11 Merck & Co. Inc. 6-(1-Hydroxyethyl)-2-SR8-1-methyl-1-carbadethiapen-2-em-3-carboxylic acid esters
JPS60104088A (ja) * 1983-11-11 1985-06-08 Sumitomo Chem Co Ltd 新規なβ−ラクタム化合物およびその製造法
CA1283906C (en) * 1983-05-09 1991-05-07 Makoto Sunagawa .beta.-LACTAM COMPOUNDS AND PRODUCTION THEREOF
US4748238A (en) * 1984-03-14 1988-05-31 Merck & Co., Inc. Crystalline 1R,5S,6S,8R-1-methyl-2-(N,N-dimethylcarbamimidoylmethylthio)-6-(1-hydroxyethyl)-1-carbapen-2-em-3-carboxylic acid
US4713451A (en) * 1984-04-09 1987-12-15 Merck & Co., Inc. Crystalline dimethyliminothienamycin
US4761408A (en) * 1984-11-02 1988-08-02 Ciba-Geigy Corporation Crystalline aminomethyl compound
NZ214691A (en) * 1984-12-27 1988-08-30 Sumitomo Pharma The preparation of carbapenem derivatives and beta-lactam intermediates
US4788282A (en) * 1985-06-07 1988-11-29 Bristol-Myers Company Deprotection of allylic esters and ethers

Also Published As

Publication number Publication date
GR3006254T3 (da) 1993-06-21
EP0256377A1 (en) 1988-02-24
NO873205D0 (no) 1987-07-30
AU7619687A (en) 1988-03-03
ES2052524T3 (es) 1994-07-16
AU596857B2 (en) 1990-05-17
FI873299A0 (fi) 1987-07-29
JP2665767B2 (ja) 1997-10-22
NO1997013I1 (no) 1997-10-17
IE60588B1 (en) 1994-07-27
FI88037C (fi) 1993-03-25
MX7534A (es) 1993-10-01
DK399087D0 (da) 1987-07-30
IL83372A0 (en) 1987-12-31
HU199473B (en) 1990-02-28
MX173359B (es) 1994-02-23
NZ221224A (en) 1989-10-27
CA1322371C (en) 1993-09-21
US4888344A (en) 1989-12-19
PH24710A (en) 1990-10-01
IL83372A (en) 1992-05-25
FI88037B (fi) 1992-12-15
EP0256377B1 (en) 1992-09-30
NO165543B (no) 1990-11-19
LU88635I2 (fr) 1995-12-01
DE3781980T2 (de) 1993-02-18
NO873205L (no) 1988-02-01
HUT44553A (en) 1988-03-28
AR243189A1 (es) 1993-07-30
HK169595A (en) 1995-11-10
FI873299L (fi) 1988-01-31
DE3781980D1 (de) 1992-11-05
IE871959L (en) 1988-01-30
DK172666B1 (da) 1999-05-10
DK399087A (da) 1988-01-31
JPS6434986A (en) 1989-02-06

Similar Documents

Publication Publication Date Title
NO170480C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenoksyeddiksyre-derivater
FI88037B (fi) Foerfarande foer framstaellning av farmaceutiskt vaerdefullt kristallint (4r,5s,6s,8r,2's,4's)-3-/4-(2-dimetylaminokarbonyl)-pyrrolidinyltio/-4-metyl-6-(1-hydroxietyl)-1-azabicyklo-/3,2,0/-hept-2-en-7-on-2-karboxylsyratrihydrat
NO168770C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzimidazolderivater
NO163406C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive imidazokinolinonderivater.
NO168303C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive heterocyklyloksoftalazinyl-eddiksyre-derivater
NO862477D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2-arylimidazol-derivater.
NO172343C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive askorbinsyrederivater
NO170629C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive dikloranilin-derivater
NO862956D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive pyrimidin-derivater.
NO167916C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive tiolaktam-n-eddiksyrederivater
NO170976C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive fenylbuten-syrederivater
NO162155C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive vinylkarbonoksylsyrederivater.
NO168299C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive alkansulfonanilid-derivater
NO164982C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
NO170582C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive aryl-piperazinyl-alkylenfenyl-heterocykliske forbindelser
NO169069C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-alkoksy-2-aminopropylaminderivater
NO165069C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive cyklopentyletere.
NO891114L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive arakidonsyre-derivater.
NO171211C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 1,3-dioksaner
NO164895C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive dikloranilinderivater.
NO171499C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5,6-dihydro-4h-cyklo-penta(b)tiofen-6-karboksylsyre-derivater
NO159590C (no) Analogifremgangsm te for fremstilling av terapeutisk aktive fenyleddiksyre-derivater.
NO167801C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 2,2'-bi-1h-imidazolderivater.
NO166322C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive nitroapovincaminsyrederivater.
NO172583C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktiv penicillansyre-derivater

Legal Events

Date Code Title Description
MK1K Patent expired